Chison Medical Technologies Co., Ltd. (SHA:688358)
China · Delayed Price · Currency is CNY 28.23
-0.12 (-0.42%)
Sep 4, 2026, 3:00 PM CST
SHA:688358 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 440.9 | 435.6 | 468.13 | 480.89 | 375.69 | 394.91 |
Other Revenue | 0.21 | 0.21 | 0.57 | 2.95 | 5.16 | 2.9 |
| 441.1 | 435.81 | 468.7 | 483.84 | 380.84 | 397.81 | |
Revenue Growth | -3.54% | -7.02% | -3.13% | 27.05% | -4.26% | 19.43% |
Cost of Revenue | 186.08 | 182.57 | 196.94 | 208.34 | 160.6 | 178.89 |
Gross Profit | 255.02 | 253.24 | 271.75 | 275.5 | 220.24 | 218.92 |
Selling, General & Admin | 91.85 | 91.13 | 92.63 | 84.26 | 81.84 | 76.15 |
Research & Development | 76.77 | 74.49 | 79.63 | 77.07 | 77.88 | 72.29 |
Other Operating Expenses | -11.58 | -2.1 | -2.68 | -3.43 | -4.3 | -2.49 |
Operating Expenses | 158.5 | 164.98 | 171.29 | 161.48 | 154.02 | 146.68 |
Operating Income | 96.52 | 88.26 | 100.47 | 114.02 | 66.22 | 72.24 |
Interest Expense | -0.31 | -0.31 | -0.38 | -0.36 | -0.11 | -0.07 |
Interest & Investment Income | 33.49 | 35.1 | 37.32 | 29.6 | 16.43 | 19.59 |
Currency Exchange Gain (Loss) | -5.95 | -5.95 | 10.48 | 5.49 | 26.13 | -6.02 |
Other Non Operating Income (Expenses) | -7.96 | -0.82 | -0.63 | -0.38 | -0.38 | -0.37 |
EBT Excluding Unusual Items | 115.79 | 116.28 | 147.26 | 148.36 | 108.29 | 85.37 |
Gain (Loss) on Sale of Investments | 0.13 | - | 0.17 | 2.93 | -1.37 | 0.43 |
Gain (Loss) on Sale of Assets | 1.79 | 4.53 | 4.61 | 2.96 | -0.5 | 30.26 |
Asset Writedown | 0.51 | - | - | - | -0.51 | -1.59 |
Other Unusual Items | 7.84 | 7.84 | 4.8 | 7.94 | 9.22 | 10.08 |
Pretax Income | 126.06 | 128.65 | 156.85 | 162.19 | 115.13 | 124.54 |
Income Tax Expense | 10.3 | 12.15 | 16.34 | 15.71 | 9.29 | 12.07 |
Net Income | 115.76 | 116.5 | 140.51 | 146.48 | 105.84 | 112.47 |
Net Income to Common | 115.76 | 116.5 | 140.51 | 146.48 | 105.84 | 112.47 |
Net Income Growth | -10.16% | -17.09% | -4.08% | 38.40% | -5.89% | 12.88% |
Shares Outstanding (Basic) | 111 | 112 | 112 | 110 | 113 | 112 |
Shares Outstanding (Diluted) | 111 | 112 | 112 | 110 | 113 | 112 |
Shares Change | -0.52% | 0.46% | 1.25% | -2.19% | 0.11% | 0.79% |
EPS (Basic) | 1.04 | 1.04 | 1.26 | 1.33 | 0.94 | 1.00 |
EPS (Diluted) | 1.04 | 1.04 | 1.26 | 1.33 | 0.94 | 1.00 |
EPS Growth | -9.70% | -17.46% | -5.26% | 41.49% | -6.00% | 12.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 75.12 | 92.76 | 131.83 | 51.9 | 11.53 | 0.78 |
Free Cash Flow Per Share | 0.67 | 0.83 | 1.18 | 0.47 | 0.10 | 0.01 |
Dividend Per Share | 0.880 | 0.880 | 1.000 | 0.800 | 0.700 | 0.357 |
Dividend Growth | -12.00% | -12.00% | 25.00% | 14.29% | 96.02% | -37.50% |
Gross Margin | 57.82% | 58.11% | 57.98% | 56.94% | 57.83% | 55.03% |
Operating Margin | 21.88% | 20.25% | 21.44% | 23.57% | 17.39% | 18.16% |
Profit Margin | 26.24% | 26.73% | 29.98% | 30.28% | 27.79% | 28.27% |
Free Cash Flow Margin | 17.03% | 21.29% | 28.13% | 10.73% | 3.03% | 0.19% |
EBITDA | 105.68 | 98.78 | 112.19 | 125.68 | 78.3 | 81.53 |
EBITDA Margin | 23.96% | 22.67% | 23.94% | 25.97% | 20.56% | 20.50% |
D&A For EBITDA | 9.16 | 10.52 | 11.72 | 11.66 | 12.07 | 9.29 |
EBIT | 96.52 | 88.26 | 100.47 | 114.02 | 66.22 | 72.24 |
EBIT Margin | 21.88% | 20.25% | 21.44% | 23.57% | 17.39% | 18.16% |
Effective Tax Rate | 8.17% | 9.44% | 10.42% | 9.69% | 8.07% | 9.69% |
Revenue as Reported | 435.81 | 435.81 | 468.7 | 483.84 | 380.84 | 397.81 |
Advertising Expenses | - | 3.55 | 5.27 | 3.38 | 2.64 | 4.1 |